Suzhou, China – September 23, 2026 -- Innovent Biologics (HKEX: 01801) will present late-breaking Phase 3 data for its CLDN18.2-targeting antibody-drug conjugate IBI343/TAK-921 at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, running October 23-27.
Phase 3 gastric cancer trial secures late-breaking oral slot
Results from the registrational G-HOPE-001 study, comparing Arcotatug Tavetecan against treatment of physician's choice in previously treated advanced gastric or gastroesophageal junction adenocarcinoma, will be delivered as a late-breaking abstract (LBA77) during the October 23 proffered paper session. Dr. Kohei Shitara of Chiba, Japan, will present the first interim analysis of the randomized, open-label trial.
IBI363 bispecific expands into first-line lung and gastric settings
Innovent will report updated Phase 1b data on IBI363/TAK-928, a PD-1/IL-2α-biased bispecific fusion protein, combined with chemotherapy as first-line treatment for advanced non-small cell lung cancer. Separate rapid oral sessions will cover IBI363 paired with XELOX chemotherapy in first-line gastric or GEJ adenocarcinoma, and IBI363 plus bevacizumab versus docetaxel in immunotherapy-resistant lung adenocarcinoma patients lacking actionable genomic alterations.
First-in-class EGFR/B7H3 ADC reports global multicenter Phase 1 results
Dr. Yi Hu of Chinese PLA General Hospital will present safety and efficacy data from a multi-regional Phase 1 study of IBI3001, an anti-EGFR/B7H3 bispecific ADC, in patients with advanced solid tumors during an October 24 proffered paper session.
HER2 ADC data targets first-line breast cancer combination therapy
Phase 2 results for IBI354 combined with pertuzumab as first-line treatment for HER2-positive, unresectable locally advanced or metastatic breast cancer will be presented by Dr. Xiaohua Zeng of Chongqing University Cancer Hospital.
Sintilimab pipeline adds six additional poster presentations
Innovent's approved PD-1 inhibitor TYVYT (sintilimab) will feature in six poster and ePoster sessions spanning non-small cell lung cancer, nasopharyngeal carcinoma, colorectal cancer and renal cell carcinoma. Studies include a CALLIOPSIS trial combining sintilimab with cetuximab and chemotherapy in MSS/pMMR, RAS/BRAF wild-type metastatic colorectal cancer, and subgroup analyses from the FRUSICA-2 trial evaluating fruquintinib plus sintilimab in advanced renal cell carcinoma.